Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 21 Aug 2019 Status changed from recruiting to suspended.
- 05 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 31 May 2017 Status changed from not yet recruiting to recruiting.